Skip to main content

Table 3 Haplotype distribution in colorectal cancer patients and normal controls

From: GSTT2 promoter polymorphisms and colorectal cancer risk

Haplotype Frequecy Distribution Healthy control (N = 568) CRC patients (N = 436) p OR(95% CI)
HT1 (G-T-G) 0.511 non-HT1/non-HT1 140 (24.6%) 99 (22.7%) 0.336 1.160 (0.857–1.571)
   HT1/non-HT1 or HT1/HT1 428 (75.4%) 337 (77.3%)   
HT2 (A-T-G) 0.422 non-HT2/non-HT2 204 (35.9%) 127 (29.1%) 0.021 1.386 (1.052–1.828)
   HT2/non-HT2 or HT2/HT2 364 (64.1%) 309 (70.9%)   
HT3 (G-C-G) 0.033 non-HT3/non-HT3 532 (93.7%) 405 (92.9%) 0.984 0.995 (0.595–1.663)
   HT3/non-HT3 36 (6.3%) 31 (7.1)   
HT4 (G-C-A) 0.032 non-HT4/non-HT4 522 (91.9%) 416 (95.4%) 0.032 0.539 (0.307–0.947)
   HT4/non-HT4 46 (8.1%) 20 (4.6%)   
  1. Adjusted for age and sex; Non-HT1 includes HT2, HT3 and HT4 but not HT1. Dominant model